Actinium Pharmaceuticals Inc ATNM
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2014-03-26 |
| Shares Out. | 31,370,000 |
| Website | actiniumpharma.com/ ↗ |
| Phone | 16466773870 |
| Employees | 25 |
| Net Income | -$5.5M |
| Free Cash Flow | -$23.0M |
| Total Assets | $45.4M |
| Total Liabilities | $43.1M |
| Equity | $2.3M |
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
Actinium Pharmaceuticals Inc is a publicly traded company under the ticker symbol ATNM on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)